Retatrutide and tirzepatide are both gut-hormone drugs, but they differ in a key way: tirzepatide is FDA-approved, while retatrutide is investigational and not approved. Here is a neutral comparison of how they work and where the research stands. This is educational, not medical advice.
| Tirzepatide | Retatrutide | |
|---|---|---|
| Receptors | GIP + GLP-1 (dual agonist) | GIP + GLP-1 + glucagon (triple agonist) |
| Status | FDA-approved (Mounjaro, Zepbound) | Investigational — not FDA-approved |
| Availability | By prescription | Clinical trials only |
Retatrutide adds a third pathway — glucagon — on top of the two that tirzepatide uses. In its clinical trials, it produced large average weight loss, among the highest reported for this class. But those are trial results for a drug still being studied; long-term safety and approval have not been established.
Tirzepatide is a real prescription option a doctor can prescribe today. Retatrutide is a research compound; the honest status is “promising in trials, not approved.” If you want to track a peptide or GLP-1 you already have, our retatrutide mixing-math page covers the arithmetic only — not a recommendation to use it.
No. As of 2026 retatrutide is investigational and not FDA-approved; it is studied in clinical trials, not sold as a prescription product.
Tirzepatide is a dual GIP/GLP-1 agonist that is approved. Retatrutide is a triple agonist that adds glucagon action and is still being studied.
In trials, retatrutide produced very large average weight loss, among the highest reported for this class — but that is trial data for an unapproved drug, and results and long-term safety are not established.
No. It is not an approved prescription product. Any product sold as retatrutide outside a trial has not been reviewed for safety or dosing.
Its long-term safety has not been established because it is still investigational. Only a physician can advise on drugs in this class.